MS News & Perspectives

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how treatment with the anti-malaria medication hydroxychloroquine may help slow disability progression among people with PPMS.Price Wooldridge, reads the column by Jamie Hughes, A Life in Letters, “Just Put One Foot in Front of the Other”.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how people in Australia with multiple sclerosis (MS) and certain other medical conditions will have access to new and expanded medications — including Kesimpta — now listed on the Pharmaceutical Benefits Scheme (PBS).Plus, Price reads the column by Jamie Hughes, A Life in Letters, “Celebrity or Not, You Matter to the MS Community”.
=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads an article about how one year of Ocrevus (ocrelizumab) treatment does not increase the risk of a rare brain infection known as PML in people with MS, a study suggests.Plus, Price reads the column by John Connor, Fall Down, Get Up Again, “On the Healing Powers of THC”.===================================
Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how treatment with evobrutinib reduced the size of inflammation-associated brain lesions in a Phase 2 trial in relapsing multiple sclerosis.Plus, Price reads the column by Jamie Hughes, A Life in Letters, “Being Prepared Can Help Us Succeed”.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Since 1985 Cyndi Zagieboylo has dedicated her life’s work to achieving National Multiple Sclerosis Society’s vision of a world free of MS. While serving on the Society's National Board of Directors as CEO and president, Cyndi serves on the Multiple Sclerosis International Federation CEO Advisory Group and Board of Trustees. A founding member of the International Progressive MS Alliance launched in 2013, Cyndi provides leadership as chair of the executive committee. The Alliance exists to expedite the development of therapies for progressive forms of MS by connecting global resources and experts.

Join the discussion as Jenn and Cyndi talk about the MS Society's many initiatives, resources, and programs. Cyndi has dedicated her life's work to achieving the National MS Society’s mission of curing MS while empowering people affected by MS to live their best lives.


Join the conversation on our MS forums: www.multiplesclerosisnewstoday.com/forums/

Follow us on social media:
Instagram - www.instagram.com/msnewstoday/
Facebook - www.facebook.com/multiplesclerosisnewstoday
Twitter - www.twitter.com/msnewstoday

For more news on Multiple Sclerosis visit:
www.multiplesclerosisnewstoday.com/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses a news article about how deep brain stimulation effectively reduces tremors in people with multiple sclerosis, according to a review study.Plus, Price Wooldridge, reads “Permanent Ink: My Tattoo Serves as an Important Reminder”, a column by Jamie Hughes.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses an article about how increasing the activity of the Myc gene can make myelin-repairing cells more efficient, a finding that may help advance MS treatments, a study says; and reads the column by John Connor, Fall Down, Get Up Again, “I’m Back in the Desert Without a Horse”.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how Immunic Therapeutics has enrolled a patient in the Phase 2 clinical trial CALLIPER, testing oral IMU-838 for progressive MS; and reads the column by Ed Tobias, MS Wire, “Sun-seeking Finds Support in New Study.”=================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how TG Therapeutics is seeking FDA approval for ublituximab, its anti-CD20 monoclonal antibody infusion therapy for RRMS and SPMS with relapses; and reads the column by Jamie Hughes, A Life in Letters, “Listening to My Body as I Experiment With a New Diet”.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit: https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses an article about how NervGen will use Imeka's biomarker imaging technology to measure changes in brain and spinal cord in its Phase 1b/2 trials.Plus, Price reads the column by John Connor, Fall Down, Get Up Again, “Party on, Dude, but I’m Still Blaming the Dog!”=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/

=====================================To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/